Clinical Study Results
LEMTRADA was studied in two 2-year clinical trials against Rebif® (interferon beta-1a), a commonly used medication for relapsing MS
A 2-year clinical trial of people who had a relapse on an MS therapy
LEMTRADA: Proven to slow confirmed disability progression in a 2-year study
People who had a relapse on an MS therapy and switched to LEMTRADA had 42% less confirmed disability progression* at 2 years compared to people receiving Rebif.
87% of people taking LEMTRADA did not experience confirmed disability progression* at 2 years, compared to 79% taking Rebif.
That means 13% of people taking LEMTRADA experienced confirmed disability progression, compared to 21% taking Rebif.
A 2-year clinical trial of people who had never been on an MS therapy.
In this study, those taking LEMTRADA had 30% less confirmed disability progression* compared with those taking Rebif, with 8% of LEMTRADA patients and 11% of Rebif patients experiencing confirmed disability progression at 2 years. The difference was not significant.
*Confirmed disability progression is defined as at least 1-point increase (1.5 for patients starting at 0) on the EDSS that lasts for 6 months.
HOW LEMTRADA WAS STUDIED
- When LEMTRADA was being studied, researchers decided to measure LEMTRADA’s effectiveness and safety against Rebif 44 mcg, a commonly prescribed MS medication. Many other studies use a placebo, or no drug at all
- This was done in two 2-year clinical trials with a total of 1191 people with relapsing MS that were chosen at random to receive either LEMTRADA or Rebif
- LEMTRADA was studied in both people who had a relapse on an MS therapy and people who had never been on an MS therapy before
Both studies included people who had experienced at least 2 relapses during the 2 years prior to
the trial, and at least 1 relapse during the year prior to the trial
Participants in Study 1 had to have rated 5.0 or lower on the Expanded Disability Status Scale
(EDSS), while participants in Study 2 rated 3.0 or lower. EDSS measures disability progression in
people with MS on a scale of 0 to 10, where 0 represents no disability
- In addition, participants in Study 1 had to have relapsed on interferon beta or glatiramer acetate